A single lysis solution for the analysis of tissue samples by different proteomic technologies

Area of Science:

• Proteomics
• Cancer Research
• Biotechnology

Background:

• Cancer remains a global health challenge, necessitating advancements in diagnostics and therapeutics.
• Translating basic research discoveries into clinical applications is crucial, yet cellular models often fail to fully represent human diseases.
• Clinically relevant samples are increasingly vital for biomarker and target discovery due to tissue heterogeneity and limitations of in vitro models.

Purpose of the Study:

• To evaluate a novel cell lysis buffer (CLB1) for its efficacy in sample preparation for proteomic analysis.
• To assess the compatibility of CLB1 with various proteomic technologies, including 2D PAGE and array-based proteomics.
• To demonstrate the utility of CLB1 in analyzing challenging and heterogeneous human tissue samples.

Main Methods:

• Utilized cell lysis buffer 1 (CLB1) for sample preparation from various human tissues.
• Performed 2D PAGE (using carrier ampholytes and immobilized pH gradient strips) to assess protein resolution.
• Applied array-based proteomics (reverse-phase lysate arrays and direct antibody arrays) to evaluate CLB1 compatibility.
• Integrated CLB1 with cryostat sectioning of frozen specimens for tissue sample preparation.

Main Results:

• CLB1 demonstrated excellent sample solubilization and high-resolution protein separation in 2D PAGE.
• The buffer proved effective for array-based proteomics, enabling direct comparison of data from different technologies.
• Successful 2D PAGE analysis was achieved on technically demanding specimens, including breast carcinoma biopsies and brain, muscle, kidney, and tongue tissues.
• CLB1, combined with cryostat sectioning, simplified tissue preparation and facilitated data integration across proteomic platforms.

Conclusions:

• Cell lysis buffer 1 (CLB1) offers a versatile and effective solution for preparing diverse human tissue samples for proteomic analysis.
• CLB1 enhances the reproducibility and comparability of data generated by different proteomic technologies, including gel-based and array-based methods.
• This approach facilitates biomarker and target discovery in cancer research by enabling robust analysis of clinically relevant samples.